Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20

Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and raises the price target from $18 to $20.